Impactos cognitivos da administração de solifenacina em doses repetidas em camundongos Swiss fêmeas

Abstract

Solifenacin succinate is an anticholinergic drug with selectivity for muscarinic receptors of M3 subtype. This drug can be used clinically in conditions of overactive bladder and urinary incontinence, diseases that affect many elderly people. On the other hand, there is a concern about solifenacin's potential to affect its users cognitively, given that elderly people – to whom this drug is commonly prescribed – are naturally affected by cognitive deficits as they age, in addition to the fact that the chronic use of anticholinergics is associated with an increased risk of cognitive decline. Thus, the aim of the present study was to evaluate cognitive alterations induced by solifenacin in female Swiss mice. Aiming at this scope, 50 animals were divided into 5 groups, one being a control, two in which there was oral administration of solifenacin for 14 days (doses of 1 or 2 mg/kg) and two for 28 days (doses of 1 or 2 mg/kg). kg). After this period, behavioral tests of open field, Y-maze, object recognition and passive avoidance were performed. In the open field test, all experimental groups did not show significant differences in the number of crossings and grooming compared to the control. However, there was a reduction in rearing in animals that received 2 mg/kg for 28 days. In the Y-maze test, there were also no differences between the experimental groups compared to the control. In the object recognition test, in turn, a dose of 2 mg/kg for 28 days significantly increased the recognition index of mice. In addition, in the passive avoidance test, there was a reduction in the latency time in all experimental groups (doses 1 or 2 mg/kg for 14 or 28 days) in relation to the control. From these results, it is concluded that solifenacin administered in repeated doses generated memory deficit in mice.